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Suicide is a global public health problemwith particular resonance for theUSmilitary.
Genetic risk factors for suicidality are of interest as indicators of susceptibility and
potential targets for intervention. We utilized population-based nonclinical cohorts
of US military personnel (discovery: N = 473 cases and N = 9778 control subjects;
replication: N = 135 cases and N = 6879 control subjects) and a clinical case-control
sample of recent suicide attempters (N = 51 cases and N = 112 control subjects) to
conduct GWAS of suicide attempts (SA). Genomewide association was evaluated
within each ancestral group (European-, African-, Latino-American) and study using
logistic regression models. Meta-analysis of the European ancestry discovery
samples revealed a genomewide significant locus in association with SA nearMRAP2
(melanocortin 2 receptor accessory protein 2) and CEP162 (centrosomal protein
162); 12 genomewide significant SNPs in the region; peak SNP rs12524136-T,
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OR = 2.88, p = 5.24E-10. These findingswerenot replicated in theEuropean ancestry
subsamples of the replication or suicide attempters samples. However, the
association of the peak SNP remained significant in a meta-analysis of all studies
and ancestral subgroups (OR = 2.18, 95%CI 1.70, 2.80). Polygenic risk score (PRS)
analyses showed some association of SA with bipolar disorder. The association with
SNPs encompassing MRAP2, a gene expressed in brain and adrenal cortex and
involved in neural control of energy homeostasis, points to this locus as a plausible
susceptibility gene for suicidality that should be further studied. Larger sample sizes
will be needed to confirm and extend these findings.
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1 | INTRODUCTION`
Suicide morbidity and mortality constitute a major global public health
problem (Whitefordet al., 2013). The age-adjusteddeath rate fromsuicide
in the United States has climbed steadily for the past 15 years (through
2014, the most recent year for which data are publicly available) and
suicide now ranks as the third leading cause of death among older
adolescents and young adults ages 15–24 (www.cdc.gov/nchs/faststas/
death.htm). Suicide is of particular concern to the US military, where
suicide attempts are among the leading causes of injury. Moreover, death
by suicide recently surpassed combat casualty as themost frequent cause
of death among active-duty Servicemembers (Armed Forces Health
Surveillance Center, 2014). Though suicide rates in the US Army have
historically been lower than in the general population, this trend has
changed in recent years (Anglemyer, Miller, Buttrey, & Whitaker, 2016)
leadingto intensivesuicidepreventionefforts (Engel,2013;Ursano,2013).
Numerous recent studies have focused on predictors of suicidality
in the US military. These studies have tended to converge upon several
risk factors shared with the civilian sector (e.g., demographics of young
adults, particularly males; depression and other mental disorders, and
history of childhood maltreatment; Afifi et al., 2016) and others unique
to the military (e.g., deployment experiences) (LeardMann et al., 2013;
Nock et al., 2014; Ramsawh et al., 2014; Ursano et al., 2015). This
attention to risk factors has extended to genetic and other biological
factors (Oquendoet al., 2016; Sudol &Mann, 2017; Turecki, 2014),with
the goal of developing a bio-signature for suicide (Oquendo et al., 2014).
Recent reports of a combined genetic–epigenetic risk marker for
suicidality in SKA2 (Guintivano et al., 2014; Kaminsky et al., 2015) are of
considerable interest, and await further replication in population-based
samples, as do other multivariate approaches that incorporate genomic
and clinical risk factors (Niculescu, Levey, Phalen, et al., 2015). Although
twin studies have documented genetic influences on suicide-related
phenotypes (heritability ∼30–55%) (Tidemalm et al., 2011), it is clear
that suicidality is a multi-determined, genetically complex trait, as is the
case for virtually all mental and behavioral disorders (Gelernter, 2015).
Thus, a great many genes and genomic processes (e.g., epistasis and
epigenetic variation) are likely to contribute to risk for suicidality, but
none have been firmly established (Niculescu, Levey, Le-Niculescu,
et al., 2015; Oquendo et al., 2014; Sokolowski, Wasserman, &
Wasserman, 2014; Turecki, 2014; Yin et al., 2016).
Several genomewide association studies (GWAS) of suicidality have
been reported (Mirkovic et al., 2016), mostly limited to analyses of suicide
attempts among patients with mood disorders. In four large GWAS
comparing mood disorder patients (bipolar and/or major depressive
disorder) with and without a history of suicide attempts, no genomewide
significant (GWS) loci were detected (Galfalvy et al., 2015; Perlis et al.,
2010; Schosser et al., 2011;Willour et al., 2012). A recent report applying
polygenic risk score (PRS) analysis to depressed patients in the RADIANT
study across suicidal ideation and suicide attempts found no genetic
overlap between those two phenotypes, leading the authors to conclude
that the tendency to think about suicide and the tendency to act on
suicidal thoughts may be influenced by substantially non-overlapping
genetic factors (Mullins et al., 2014). There is only partial overlap in
epidemiological risk factors for suicidal ideation and attempts (Nock et al.,
2013). Thus, genetic factors influencing these various facets of suicidality
may also be different and should be examined separately.
In the present study, we utilized population-based nonclinical
cohorts of USmilitary personnel and one clinical sample from the same
US military population to conduct GWAS of suicide attempts (SA). We
also used genomewide genotype data to examine polygenic risk for SA
in relation to Psychiatric Genomics Consortium (PGC) PRS for major
depressive disorder (Ripke et al., 2013), bipolar disorder (Psychiatric,
2011), and cross-disorder diagnoses (Cross-Disorder Group of the
Psychiatric Genomics et al., 2013).
2 | METHODS
2.1 | Subjects
Data come from several components of the Army Study To Assess Risk
and Resilience in Servicemembers (STARRS): New Soldier Study (NSS),
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Pre-/Post-Deployment Study (PPDS), and Soldier Health Outcomes Study
A (SHOS-A). Detailed information about the design and conduct of
STARRS is available in a separate report (Ursano et al., 2014) and in the
Supplemental Materials. Soldiers from the respective studies de-
scribed below are unique and independent as confirmed by analysis of
genetic relatedness.
2.1.1 | New soldier study (NSS)
The NSS was carried out among new soldiers at the start of their
basic training at three Army Installations between April 2011 and
November 2012. In the NSS, reports of lifetime SA refer to their pre-
military experiences. Of 39,784 NSS respondents who completed the
Self AdministeredQuestionnaire (SAQ), 33,088 (83.2%) provided blood
samples. All cases of reported lifetime suicide attempt (SA) were
genotyped. The first 17,868 eligible respondents were subsampled for
genotyping as follows: (1) respondents with DSM-IV lifetime disorders
of principal interest (major depressive disorder, generalized anxiety
disorder, panic disorder, PTSD, suicide attempt [SA], other deliberate
self-harm) sampled at 100% [N = 4,024] and (2) a subset of respondents
with none of the disorders of principal interest, stratum-matched on
sex, service type (Regular Army vs. Guard/Reserve), and childhood
adversity quartile (detailed description available on request from the
authors) [N = 3,975]. In total this yielded 7,999NSS1 respondents with
eligibleSAQresponseswhoseblood-extractedDNAwasgenotyped for
GWAS. When the remaining half (N = 15,220) of the cohort collection
was completed, all cases of PTSD and suicide attempt (SA) were
selected for genotyping along with a set of controls matched to these
cases as described above for NSS1) as a potential replication sample.
This yielded an additional 2,835 NSS genotyped respondents; we refer
to this component of the study as NSS2.
2.1.2 | Pre-/post-deployment survey (PPDS)
The PPDS collected baseline data from US Army soldiers in three
Brigade Combat Teams (BCTs) during the first quarter of 2012, within
approximately 6 weeks of their upcoming deployment to Afghanistan.
A total of 9,949 Soldiers were present for duty in the 3 BCTs; 9,488
(95.3%) consented to participate in the survey with 8,558 (86.0%)
providing complete baseline survey responses and consent to link their
survey responses to their administrative records. Of these, 7,927
PPDS soldiers with eligible baseline SAQ responses and genomewide
data are included here.
2.1.3 | Soldier health outcomes study A (SHOS-A)
The SHOS-A is a clinical case-control study of soldiers hospitalized
following an acute suicide attempt. This study compared soldiers who
attempted suicide (cases) with non-hospitalized Army controls without
lifetime suicide attempts matched on a variety of measures including
demographics, general psychiatric distress, and psychiatric disorder.
The 95 cases and 168 controls for which DNA samples were available
are included.
2.2 | Measures
The SAQ surveyed socio-demographic characteristics including
lifetime and past-30-day mental disorders, and an array of potential
risk and resilience factors. SHOS-A included additional information
about the circumstances of the index suicide attempt.
2.2.1 | Suicidality assessment
Suicidal behaviors were assessed using a version of the Columbia
Suicidal Severity Rating Scale (C-SSRS) (Posner et al., 2011) assessing
lifetime occurrence of suicide ideation (“Did you ever in your life have
thoughts of killing yourself” or “Did you ever wish you were dead or would
go to sleep and never wake up?”) and, among respondents who reported
lifetime suicide ideation, suicide plans (“Did you ever have any intention
to act [on these thoughts/on that wish]?” and, if so, “Did you ever think
about how you might kill yourself [e.g., taking pills, shooting yourself] or
work out a plan of how to kill yourself?”) and suicide attempts (“Did you
ever make a suicide attempt [i.e., purposefully hurt yourself with at least
some intention to die]?”). For the primary analysis, controls are those
individuals with no lifetime history of SA (who may or may not have a
lifetime history of suicidal ideation).
2.3 | Genetic data collection and procedures
NSS1 and PPDS samples were genotyped using the Illumina
OmniExpress + Exome array with additional custom content. NSS2
and SHOS-A samples were genotyped on the Ilumina PsychChip.
Quality control (QC) of genotype data used standard protocols as
described elsewhere (Stein et al., 2016). Relatedness testing was
carried out with PLINK v1.90 (Chang et al., 2015) and, for pairs of
subjects with π of >0.2, onemember of each relative pair was removed
at random.
Genotype imputation was performed with a 2-step pre-phasing/
imputation approach with a reference multi-ethnic panel from 1000
Genomes Project (August 2012 phase 1 integrated release; 2,186
phased haplotypes with 40,318,245 variants). We removed SNPs that
were not present in the 1000 Genomes Project reference panel, had
non-matching alleles to 1000 Genome Project reference, or with
ambiguous, unresolvable alleles (AT/GC SNPs with minor allele
frequency [MAF] >0.1). A total of 664,457 SNPs for the Illumina
OmniExpress array and 360,704 for the Illumina PsychChip entered
the imputation.
We performed the following quality control procedure to obtain
the genotype data for population assignment (see Supplemental
Materials) and principal components analysis (PCA). We retained
autosomal SNPs with missing rate <0.05; samples with individual-wise
missing rate <0.02; SNPs with missing rate <0.02; and SNPs with
missing rate difference between cases and controls <0.02. After QC,
we merged our study samples with HapMap3 samples. We retained
SNPs with MAF ≥0.01 and performed LD pruning at R2 > 0.02. Finally,
we excluded SNPs in MHC region (Chr 6:25–35Mb) and Chr 8
inversion (Chr 8:7–13Mb).
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FIGURE 1 Lifetime suicide attempt cases versus non-suicide attempt controls, NSS(1,2). (a) Manhattan plot (left side) and quantile–quantile
plot (right side) for genome-wide association study of lifetime suicide attempt, controlling for 10 ethnicity-specific principal components in
European (EUR) sample. (b) Manhattan plot (left side) and quantile-quantile plot (right side) for genome-wide association study of lifetime
suicide attempt, controlling for ten ethnicity-specific principal components in African (AFR) sample. (c) Manhattan plot (left side) and quantile–
quantile plot (right side) for genome-wide association study of lifetime suicide attempt, controlling for ten ethnicity-specific principal
components in Latino (LAT) sample [Color figure can be viewed at wileyonlinelibrary.com]
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2.4 | Statistical analysis
2.4.1 | Genomewide association study (GWAS)
GWAS were conducted in PLINK v1.90 (Chang et al., 2015) using the
logistic regression model, the allelic dosage files generated from
imputation, and controlling for PCs 1–10 within ancestry. Since
STARRS subjects are from diverse ancestral backgrounds, GWASwere
conducted in NSS1 and NSS2 separately within the three ancestral
groups (European [EUR], African [AFR], or Latino [LAT]; excluded was
an Asian [ASI] group that was too small for separate analysis based on
PCs) and then meta-analyzed within ancestry group across both
studies. Meta-analysis was conducted using an inverse-weight fixed
effects model in PLINK. We filtered out SNPs with MAF < 0.01,
imputation quality score (INFO) < 0.8). In order to investigate whether
there were multiple independent signals within any meta-analytic
regions with several genome-wide significant results, we tested for
association between each SNP in the region and the outcome,
conditioned on the SNP most significantly associated with the
outcome. We used the NSS(1,2) meta-analysis results as our
discovery dataset, and tested for consistency of results within PPDS
and SHOS-A.
2.4.2 | Polygenic risk scores (PRS)
PRS analyses for the SA phenotype were computed using PLINK in the
EUR subsamples only because of the unavailability of reference GWAS
data for the other populations with no LD trimming (Chang et al.,
2015). p-Value thresholds of 0.001, 0.01, 0.05, and 0.3 and 1 were
chosen as cutoffs for SNP inclusion in the training samples. The PGC
Major Depression, Bipolar Disorder, Schizophrenia, Attention-Deficit/
Hyperactivity Disorder, and Cross Disorder analyses were used as the
training sample and the PRS was evaluated in NSS(1,2), PPDS,
and SHOS-A, combined. Logistic models, controlling for cohort and
within-ethnicity PCs 1–10 were run at each of the five thresholds, for
each training/target sample combination. Best call genotypes were
created from the 1000G imputation probabilities with imputation
quality >0.9 and all available overlapping SNPs between the cohorts
and the training samples were used. While we have included PRSs at
five different p-value thresholds, these scores are highly correlated and
straight Bonferroni correctionwould result in a significance level that is
too conservative, we have chosen to use 0.031 as our significance level
(assuming the five scores are correlated at r = 0.7 across the five
thresholds). We also conducted a Fisher's test of combined probability
across cohorts: X22k ∼  2∑ki¼1lnðpiÞ.
3 | RESULTS
3.1 | Sociodemographic characteristics and lifetime
suicide attempt prevalence
Table 1 shows the case and control counts and their ratio for each
study by ancestry. Also included in the table is the proportion of
subjects in each group with a lifetime history of major depressive
episode(s). Prevalence of lifetime SA in PPDS corresponded to US
Army population estimates with approximately 2% lifetime SA. The
other samples, which have higher proportions of soldiers with lifetime
history of SA, had been purposefully enriched for SA cases, with NSS
cases being selected from a larger population and SHOS-A being a
clinical study of soldiers with SA.
3.2 | Suicide attempts (SA)
Figure 1a–c shows the results of the SA GWAS meta-analyses of
NSS(1,2) in the three ancestral groups; no inflation of test statisticswas
observed in the GWAS NSS meta-analytic results (λ = 0.98–1.00).
There was one genome-wide significant (GWS) SNP in the AFR group,
rs144662392, p = 7.65 × 10−9, but it was a lone SNP and considered
FIGURE 2 Region around genome-wide significant SNPs from the European ancestry NSS(1,2) discovery meta-analysis, chr6:[84303043–
85303043], hg19, (a) before adjustment for history of major depressive episode and (b) after adjustment for lifetime history of major
depressive episode [Color figure can be viewed at wileyonlinelibrary.com]
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likely to be a spurious finding. One gene region, all within a span of
∼200 K bp located on Chr 6, had several loci with meta-analytic
GWS results for SA in the EUR group. Many of the SNPs are in high
LD (r2 ≥ 0.8). The regional plot in Figure 2a shows that the signal is near
the MRAP2 and CEP162 (also known as KIAA1009 or QN1) genes on
Chr 6. Figure 2b shows that the signal remains with multiple
genomewide significant results even when adjusted for lifetime major
depression.
Table 2 provides the NSS meta-analyzed GWS results in the
NSS(1,2) meta-analysis for the EUR group and their corresponding
results in the PPDS and SHOS-A EUR analyses. (Results for these same
SNPs in the AFR and LAT samples, none of which are statistically
significant, are shown in Supplementary Table S1.) Adjusting for
history of lifetimemajor depressive episode, the NSS(1,2) effects are in
the same direction and of similar magnitude, and most remain
genomewide significant (Table 2). This suggests that the region is
not just operating through major depression to influence SA.
SNP lookups of top results frompreviousGWAS suicidality studies
(Galfalvy et al., 2015; Perlis et al., 2010; Schosser et al., 2011; Willour
et al., 2012) showed no statistically significant replication in any of our
studies (Supplementary Table S2). We collaborated with the VA Mid-
Atlantic MIRECC Workgroup to evaluate our top result in the
European ancestry sample of their Iraq-Afghanistan era veteran
cohort.(Ashley-Koch et al., 2015) Although our top SNP was not
assayed, there is a proxy SNP (rs17187076) in complete LD with our
top SNP (rs12524136) in their dataset that was nominally significant
(p = 0.025; p = 0.008 adjusted for lifetime major depressive episode)
for lifetime SA. The results for the top EUR GWS SNP (rs12524136) in
all studies and ancestral groups is shown as a Forest Plot in Figure 3.
The fixed-effects meta-analysis shows an overall statistically signifi-
cant effect, which appears to be driven by effects in the European
subjects.
3.3 | Polygenic risk scores (PRS)
Table 3 presents our analysis of PRS of SA.We usedGWAS analyses of
MDD (Ripke et al., 2013), bipolar disorder (Psychiatric, 2011),
schizophrenia (Schizophrenia Working Group of the Psychiatric
Genomics, 2014), attention-deficit/hyperactivity disorder (Neale
et al., 2010), and a cross disorder analysis (Cross-Disorder Group of
the Psychiatric Genomics et al., 2013) conducted by the international
PGC to construct PRS which were then used to predict SA in NSS(1,2),
PPDS, and SHOS-A. The PGC-Bipolar disorder PRS showed a
relationship with SA in the PPDS and SHOS-A samples (and in a
combined cohort analysis [Supplementary Table S3]) at multiple
p-value cutoff thresholds (Table 3).
3.4 | Gene-based and pathway analyses
We performed gene and pathway enrichment analyses on the NSS1,
NSS2 and PPDS results meta-analyzed for European, African and
Latino American samples, without adjustment for MDE. There was no
gene showing significant results after Bonferroni correction for the
number of genes tested (N = 18,191) using MAGMA (de Leeuw et al.,
2015) (See also Supplemental Materials for pathway analyses).
4 | DISCUSSION
This is, to our knowledge, the first population-based genome-wide
association examination of suicide attempts (SA), in the military or
otherwise. Whereas a variety of biological risk factors are relatively
well established for suicide attempt behavior (Sudol & Mann, 2017),
genome-wide association studies provide the opportunity to discover
biological systems that had not previously been implicated. Prior
genetic association studies of suicidality have relied on clinical or other
targeted samples, primarily patients with mood disorders (Galfalvy
et al., 2015; Perlis et al., 2010; Schosser et al., 2011; Willour et al.,
2012), or patients taking antidepressant medication (Menke et al.,
2012; Perroud et al., 2012). Since suicide attempts occur at substantial
rates outside of clinically identified samples, examining non-clinical,
population-based samples is important to fully understand genetic and
other risk factors for SA, which may differ depending on sample
characteristics (Mirkovic et al., 2016).We focused on soldiers in the US
Army, where better understanding and prevention of suicidality has
been amajor concern (Engel, 2013; LeardMann et al., 2013;Nock et al.,
2014; Ursano et al., 2015).
We identified one GWS region in the EUR NSS(1,2) meta-analysis
that includes the genes CEP162 (involved in ciliary function andmitotic
spindle assembly (Leon, Omri, Gely, Klein, & Crisanti, 2006; Wang
et al., 2013) andMRAP2 (melanocortin 2 receptor accessory protein 2),
a paralogue of MRAP. A role for CEP162, involved in required to
promote assembly of the transition zone in primary cilia (Wang et al.,
2013), cannot be discounted, though it is not an obvious candidate.
The product ofMRAP2, M2CR accessory protein, supports M2CR cell
surface expression necessary for the production of a functional ACTH-
responsive melanocortin receptor (Chan et al., 2009; Novoselova,
Jackson, Campbell, Clark, & Chan, 2013).MRAP2 is expressed in brain
FIGURE 3 Forest plot and fixed effects meta-analysis for lifetime
suicide attempt for top SNP in MRAP2
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and adrenal tissue, where it is involved with neural control of energy
homeostasis, possibly through Mrap2 interaction with the melano-
cortin-4-receptor (Mc4r) affecting receptor signaling (Dores, Liang,
Davis, Thomas, & Petko, 2016; Jackson, Ramachandrappa, Clark, &
Chan, 2015). Loss ofMRAP2 function has been linked to obesity (Asai
et al., 2013) but, to the best of our knowledge, has not been previously
linked to suicidality or depressive illness. Given the presumed
importance of HPA-axis function and glucocorticoid regulation in
depressive illness and suicidality, these observations in concert with
the findings that rare MRAP mutations may cause primary adrenal
insufficiency (Guran et al., 2016) suggest that sequencing of this region
may yield new insights into the genetic bases for suicidality.
Recent work with polygenic risk scores (PRSs) for suicide attempts
in other cohorts has pointed to a role for neurodevelopmental genes
(Sokolowski, Wasserman, & Wasserman, 2016), though MRAP2 or
CEP162, per se, were not specifically mentioned in that report. We
observed an association between a PRS derived from the PGC-bipolar
disorder analysis and SA in PPDS and SHOS-A. Although these
associations were quite modest and require replication, they are
consistent with the hypothesis of shared genetic risk between SA and
bipolar disorder. A further caveat in interpreting these PRS associa-
tions is that we did not consider bipolar disorder in our case-control
definitions. It is therefore conceivable that the PRS associations seen
with bipolar disorder and SA may reflect an excess of bipolar disorder
in cases. Similarly, although we did adjust for major depressive episode
in sensitivity analyses of the EUR sample and found no appreciable
decrement in the strength of association with MRAP2/CEP162, it is
conceivable that other disorders (e.g., PTSD) associated with SA might
be confounders of this association. Additional research with larger
samples will be needed to exclude this possibility.
Our results should also be interpreted in light of several other
limitations. The small sample size and likely heterogeneity may explain
the failure to see the GWS results forMRAP2/CEP162 extend into the
PPDS or SHOS-A samples, both of which contained far fewer numbers
of SA cases than the NSS discovery sample. The NSS sample, it should
be remembered, was based on reporting of SA prior to entering the
military. Future studies will need to address this heterogeneity either
by stratifying phenotypes differently (e.g., early-onset SA), incorpo-
rating informative covariates that may improve power (e.g., childhood
maltreatment history or other psychosocial risk factors for SA)
(Kaminsky et al., 2015), or attaining much larger sample sizes. Lastly,
we recognize that the findings from this study may not generalize
beyond military personnel who have self-selected for service and may
also have unique experiences as part of military service. Additionally,
our sample is mostly male. It may be that the genetic factors
influencing suicidality vary by sex, but we lacked the power to test this
hypothesis.
In summary, despite this being the largest population-based
GWAS study of SA to date, and the first in military population-based
cohorts, the number of cases was small. The meta-analytic association
of SNPs encompassingMRAP2, a gene expressed in brain and adrenal
cortex and involved in neural control of energy homeostasis, points to
this locus as a credible susceptibility gene for suicidality whose
function should be further studied in larger human subject samples and
in animal models of suicidal behaviors (Gould et al., 2017).
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